Nivolumab + Relatlimab + Ipilimumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Timeline
Dec 20, 2019 → Oct 31, 2026
NCT ID
NCT04080804About Nivolumab + Relatlimab + Ipilimumab
Nivolumab + Relatlimab + Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04080804. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC).
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04080804 | Phase 2 | Recruiting |
| NCT03724968 | Phase 2 | Terminated |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)